Interstitial lung disease in Japanese patients with lung cancer: A cohort and nested case-control study

American Journal of Respiratory and Critical Care Medicine

Volumn 177, Issue 12, 2008, Pages 1348-1357

  Kudoh, Shoji ^a   Kato, Harubumi ^b   Nishiwaki, Yutaka ^c   Fukuoka, Masahiro ^d   Nakata, Kouichiro ^e   Ichinose, Yukito ^f   Tsuboi, Masahiro ^b   Yokota, Soichiro ^g   Nakagawa, Kazuhiko ^d   Suga, Moritaka ^h   Jiang, Haiyi ^j   Itoh, Yohji ^j   Armour, Alison ^j   Watkins, Claire ^j   Higenbottam, Tim ^j,k   Nyberg, Fredrik ^l,m   Johkoh, Takeshi ⁱ   Takahashi, Masashi ⁱ   Ohno, Yoshiharu ⁱ   Kusumoto, Masahiko ⁱ   Arakawa, Hiroaki ⁱ   Sakai, Fumikazu ⁱ   more..

^a NIPPON MEDICAL SCHOOL   (Japan)

^b TOKYO MEDICAL UNIVERSITY HOSPITAL   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^d KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e Nakata Clinic   (Japan)

^f NATIONAL KYUSHU CANCER CENTER   (Japan)

^g TONEYAMA NATIONAL HOSPITAL   (Japan)

^h SAISEIKAI KUMAMOTO HOSPITAL   (Japan)

ⁱ Japan Thoracic Radiology Group   (Japan)

^j ASTRAZENECA   (United Kingdom)

^k UNIVERSITY OF SHEFFIELD   (United Kingdom)

^l ASTRAZENECA R AND D   (Sweden)

^m KAROLINSKA INSTITUTE   (Sweden)

more..

Author keywords

Chemotherapy; Gefitinib; Interstitial lung disease; Japanese patients; Non small cell lung cancer

Indexed keywords

GEFITINIB; GEMCITABINE; NAVELBINE; PLATINUM; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HUMAN; INCIDENCE; INTERSTITIAL LUNG DISEASE; JAPANESE; LOGISTIC REGRESSION ANALYSIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT CANCER; RISK; RISK FACTOR; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; JAPAN; KAPLAN MEIER METHOD; LUNG TUMOR; MIDDLE AGED; MORTALITY; STATISTICAL MODEL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; FEMALE; HUMANS; INCIDENCE; JAPAN; KAPLAN-MEIERS ESTIMATE; LOGISTIC MODELS; LUNG DISEASES, INTERSTITIAL; LUNG NEOPLASMS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RISK FACTORS;

EID: 44949199171     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200710-1501OC     Document Type: Article

References (30)

1. American Thoracic Society. American Thoracic Society/European Respiratory Society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2002;165:277-304.
2. Inoue A, Saijo Y, Maemondo M, Gomi K, Tokue Y, Kimura Y, Ebina M, Kikuchi T, Moriya T, Nukiwa T. Severe acute interstitial pneumonia and gefitinib. Lancet 2003;361:137-139.
3. Kondoh Y, Taniguchi H, Kawabata Y, Yokoi T, Suzuki K, Takagi K. Acute exacerbation in idiopathic pulmonary fibrosis: analysis of clinical and pathologic findings in three cases. Chest 1993;103:1808-1812.
4. Wells AU, Hogaboam CM. Update in diffuse parenchymal lung disease 2006. Am J Respir Crit Care Med 2007;175:655-660.
5. Raghu G, Nyberg F, Morgan G. The epidemiology of interstitial lung disease and its association with lung cancer. Br J Cancer 2004;91:S3-S10.
6. Kudoh S, Takeda K, Nakagawa K, Takada M, Katakami N, Matsui K, Shinkai T, Sawa T, Goto I, Semba H, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 2006;24:3657-3663.
7. Abid SH, Malhotra V, Perry MC. Radiation-induced and chemotherapy-induced pulmonary injury. Curr Opin Oncol 2001;13:242-248.
8. Ando M, Okamoto I, Yamamoto N, Takeda K, Tamura K, Seto T, Ariyoshi Y, Fukuoka M. Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2006;24:2549-2556.
9. Danson S, Blackhall F, Hulse P, Ranson M. Interstitial lung disease in lung cancer: separating disease progression from treatment effects. Drug Saf 2005;28:103-113.
10. Rossi SE, Erasmus JJ, McAdams HP, Sporn TA, Goodman PC. Pulmonary drug toxicity: radiologic and pathologic manifestations. Radiographics 2000;20:1245-1259.
11. Sandler AB, Nemunaitis J, Denham C, von Pawel J, Cormier Y, Gatzemeier U, Mattson K, Manegold C, Palmer MC, Gregor A, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000;18:122-130.
12. Azuma A, Kudoh S. High prevalence of drug-induced pneumonia in Japan. Japan Medical Association Journal 2007;50:405-411.
13. Koo L, Clark J, Quesenberry CP, Higenbottam T, Nyberg F, Wolf M, Steinberg M, Forsythe B. National differences in reporting "pneumonia" and "pneumonia interstitial": an analysis of the WHO drug monitoring database on 15 drugs in nine countries for seven pulmonary conditions. Pharmacoepidemiol Drug Saf 2005;14:775-787.
14. Nyberg F, Hada S, Rothman KJ; Iressa CCS Collaborator Group. IRESSA and interstitial lung disease (ILD) in Japan: lessons from a large nested case-control study to evaluate a safety issue [abstract]. Pharmacoepidemiol Drug Saf 2006;15:S287.
15. Kudoh S, Kato H, Nishiwaki Y, Fukuoka M, Nakata K, Suga M, Jiang H, Itoh Y, Higenbottam T, Nyberg F; Japan Thoracic Radiology Group. A cohort and nested case-control study to quantify the risk of interstitial lung disease (ILD) in Japanese patients with NSCLC treated with gefitinib or chemotherapy [abstract]. Am J Respir Crit Care Med 2007;175:A148
16. Pearce N. What does the odds ratio estimate in a case-control study? Int J Epidemiol 1993;22:1189-1192.
17. Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Sturmer T. Variable selection for propensity score models. Am J Epidemiol 2006;163:1149-1156.
18. Hotta K, Kiura K, Tabata M, Harita S, Gemba K, Yonei T, Bessho A, Maeda T, Moritaka T, Shibayama T, et al. Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group. Cancer J 2005;11:417-424.
19. Takano T, Ohe Y, Kusumoto M, Tateishi U, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Tamura T, et al. Risk factors for interstitial lung disease and predictive factors for tumor response in patients with advanced non-small cell lung cancer treated with gefitinib. Lung Cancer 2004;45:93-104.
20. AstraZeneca KK Japan. Japanese patient information for IRESSA, version 17 [in Japanese]. Osaka, Japan: AstraZeneca KK Japan; October 2006.
21. Japan Lung Cancer Society Committee on Preparation of Guideline for Use of Gefitinib. Guideline for use of gefitinib. Chiba, Japan: The Society; 2005. In Japanese.
22. Chang A, Parikh P, Thongprasert S, Tan E-H, Perng R-P, Ganzon D, Yang C-H, Tsao C-J, Watkins C, Botwood N, et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol 2006;1:847-855.
23. Hirsch FR, Varella-Garcia M, Bunn Jr PA, Franklin WA, Dziadziuszko R, Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006;24:5034-5042.
24. Pao W, Miller VA. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions. J Clin Oncol 2005;23:2556-2568.
25. Yoshida S. The results of gefitinib prospective investigation [in Japanese]. Medicine and Drug Journal 2005;41:772-789.
26. Armour A. Gefitinib in advanced non-small cell lung cancer: clinical experience in patients of Asian origin. Asia Pac J Clin Oncol 2007;3:66-78.
27. Modi S, Seidman AD. An update on epidermal growth factor receptor inhibitors. Curr Oncol Rep 2002;4:47-55.
28. Ishii Y, Fujimoto S, Fukuda T. Gefitinib prevents bleomycin-induced lung fibrosis in mice. Am J Respir Crit Care Med 2006;174:550-556.
29. Rice AB, Moomaw CR, Morgan DL, Bonner JC. Specific inhibitors of platelet-derived growth factor or epidermal growth factor receptor tyrosine kinase reduce pulmonary fibrosis in rats. Am J Pathol 1999;155:213-221.
30. Suzuki H, Aoshiba K, Yokohori N, Nagai A. Epidermal growth factor receptor tyrosine kinase inhibition augments a murine model of pulmonary fibrosis. Cancer Res 2003;63:5054-5059.